In vitro release of propofol and binding capacity with regard to plasma constituents

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 70, Issue 3, 2008, Pages 882-888

  Schicher, Maximilian ^a   Polsinger, Margit ^b   Hermetter, Albin ^a   Prassl, Ruth ^c   Zimmer, Andreas ^b  

^a GRAZ UNIVERSITY OF TECHNOLOGY   (Austria)

^b UNIVERSITY OF GRAZ   (Austria)

^c ERICH SCHMID INSTITUTE OF MATERIALS SCIENCE   (Austria)

Author keywords

Drug release; Lipoproteins; Parenteral drugs; Propofol; Serum proteins

Indexed keywords

ALBUMIN; GENERIC DRUG; LIPOPROTEIN; LIPURO; LONG CHAIN TRIACYLGLYCEROL; LOW DENSITY LIPOPROTEIN; MEDIUM CHAIN TRIACYLGLYCEROL; PROPOFOL; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DRUG FORMULATION; DRUG RELEASE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; PHASE SEPARATION; ULTRACENTRIFUGATION;

ANESTHETICS, INTRAVENOUS; EMULSIONS; HUMANS; KINETICS; LIPOPROTEINS, LDL; PROPOFOL; PROTEIN BINDING; SERUM ALBUMIN; SOLUBILITY;

EID: 54949085376     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2008.06.018     Document Type: Article

References (23)

1. Baker M.T., and Naguib M. Propofol - the challenges of formulation. Anesthesiology 103 (2005) 860-876
2. Mazoit J.X., and Samii K. Binding of propofol to blood components: implications for pharmacokinetics and for pharmacodynamics. Br. J. Clin. Pharmacol. 47 (1999) 35-42
3. Williams D.B., and Akabas M.H. Structural evidence that propofol stabilizes different GABA(A) receptor states at potentiating and activating concentrations. J. Neurosci. 22 (2002) 7417-7424
4. Zamacona M.K., Suarez E., Garcia E., Aguirre C., and Calvo R. The significance of lipoproteins in serum binding variations of propofol. Anesth. Analg. 87 (1998) 1147-1151
5. de la Fuente L., Lukas J.C., Vazquez J.A., Jauregizar N., Calvo R., and Suarez E. 'In vitro' binding of propofol to serum lipoproteins in thyroid dysfunction. Eur. J. Clin. Pharmacol. 58 (2002) 615-619
6. Levitt D.G., and Schnider T.W. Human physiologically based pharmacokinetic model for propofol. BMC Anesthesiol 5 (2005) 4
7. Babl J. New formulation of propofol in an LCT/MCT emulsion. Eur. Hosp. Pharm. 1 (1995) 15-21
8. Doenicke A.W., Roizen M.F., Rau J., Kellermann W., and Babl J. Reducing pain during propofol injection: the role of the solvent. Anesth. Analg. 82 (1996) 472-474
9. Knibbe C.A.J., Voortman H.J., Aarts L., Kuks P.F.M., Lange R., Langemeijer H.J.M., and Danhof M. Pharmacokinetics, induction of anaesthesia and safety characteristics of propofol 6% SAZN vs propofol 1% SAZN and Diprivan (R)-10 after bolus injection. Br. J. Clin. Pharmacol. 47 (1999) 653-660
10. Jungheinrich C., Scharpf R., Wargenau M., Dilger C., and Bepperling F. Pharmacokinetics of the generic formulation propofol 1% Fresenius in comparison with the original formulation (Disoprivan (R) 1%). Clin. Drug Invest. 22 (2002) 417-427
11. Kostner G.M., and Laggner P. Chemical and physical properties of lipoproteins. In: Fruchart J.C., and Shepard J. (Eds). Lipoproteins: Clinical, Biochemistry, Principles, Methods, and Applications (1989), Walter de Gruyter, New York 23-54
12. Roach P.D., and Noel S.P. Biotinylation of low density lipoproteins via free amino groups without loss of receptor binding activity. J. Lipid Res. 28 (1987) 1508-1514
13. Daerr W.H., Pethke W., Windler E.T., and Greten H. Biotinyl-high-density lipoproteins as a probe for the determination of high-density lipoprotein turnover in humans. Biochim. Biophys. Acta 1043 (1990) 311-317
14. Levy M.Y., and Benita S. Drug release from submicronized o/w emulsion: a new in vitro kinetic evaluation model. Int. J. Pharm. 66 (1990) 29-37
15. Washington C. Drug release from microdisperse systems: a critical review. Int. J. Pharm. 58 (1989) 1-12
16. Washington C. Evaluation of non-sink dialysis methods for the measurement of drug release from colloids: effects of drug partition. Int. J. Pharm. 56 (1989) 71-74
17. Qi K., Al-Haideri M., Seo T., Carpentier Y.A., and Deckelbaum R.J. Effects of particle size on blood clearance and tissue uptake of lipid emulsions with different triglyceride compositions. J. Parenter. Enteral Nutr. 27 (2003) 58-64
18. Pownall H.J., and Ehnholm C. The unique role of apolipoprotein A-I in HDL remodeling and metabolism. Curr. Opin. Lipidol. 17 (2006) 209-213
19. Rosseneu M., Soetewey F., Blaton V., Lievens J., and Peeters H. Application of microcalorimetry to the study of lipid-protein interaction. Chem. Phys. Lipids 17 (1976) 38-56
20. Arai H., Yamamoto A., Matsuzawa Y., Saito Y., Yamada N., Oikawa S., Mabuchi H., Teramoto T., Sasaki J., Nakaya N., Itakura H., Ishikawa Y., Ouchi Y., Horibe H., Egashira T., Hattori H., Shirahashi N., and Kita T. Polymorphisms in four genes related to triglyceride and HDL-cholesterol levels in the general Japanese population in 2000. J. Atheroscler. Thromb. 12 (2005) 240-250
21. Huang A.Q., Hu Y.H., Zhan S.Y., Xu B., Pang Z.C., Cao W.H., Lu J., Qin Y., and Lee L.M. Lipoprotein lipase gene S447X polymorphism modulates the relation between central obesity and serum lipids, a twin study. Int. J. Obes. 30 (2006) 1693-1701
22. Miller W.M., Nori-Janosz K.E., Lillystone M., Yanez J., and McCullough P.A. Obesity and lipids. Curr. Cardiol. Rep. 7 (2005) 465-470
23. Eisenberg S., Gavish D., Oschry Y., Fainaru M., and Deckelbaum R.J. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment. J. Clin. Invest. 74 (1984) 470-482